Secukinumab vs. Adalimumab for treatment of ankylosing spondylitis: A cost per responder analysis at 52 weeks from an Argentinian perspective

Category Primary study
JournalValue in Health
Year 2017
This article has no abstract
Epistemonikos ID: d0d80c3809a065407d13c05a1e5626c100dc7b7c
First added on: Feb 08, 2025